CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Reaffirmed by Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a report published on Monday morning, Benzinga reports. The firm currently has a $88.00 price objective on the stock. CRSP has been the subject of several other research reports. Oppenheimer decreased their target price on CRISPR Therapeutics […]
More Stories
FY2025 EPS Estimates for Vecima Networks Lowered by B. Riley
Vecima Networks Inc. (TSE:VCM – Free Report) – B. Riley dropped their FY2025 earnings per share (EPS) estimates for Vecima...
Scotiabank Issues Pessimistic Estimate for EQB Earnings
EQB Inc. (TSE:EQB – Free Report) – Equities researchers at Scotiabank reduced their FY2025 EPS estimates for shares of EQB...
Analysts Set Expectations for Hancock Whitney Q3 Earnings
Hancock Whitney Co. (NASDAQ:HWC – Free Report) – Stock analysts at Zacks Research boosted their Q3 2025 earnings per share...
William Blair Reduces Earnings Estimates for Kura Sushi USA
Kura Sushi USA, Inc. (NASDAQ:KRUS – Free Report) – Analysts at William Blair decreased their Q2 2025 earnings estimates for...
Polyhedra Network (ZKJ) Reaches 24 Hour Trading Volume of $5.30 Million
Polyhedra Network (ZKJ) traded 0.2% lower against the US dollar during the 1 day period ending at 7:00 AM E.T....
BSF Enterprise (LON:BSFA) Shares Up 18.7% – Should You Buy?
BSF Enterprise Plc (LON:BSFA – Get Free Report)’s share price was up 18.7% during trading on Friday . The company...